Cargando…

Integrated multigene expression panel to prognosticate patients with gastric cancer

Most of the proposed individual markers had limited clinical utility due to the inherent biological and genetic heterogeneity of gastric cancer. We aimed to build a new molecular-based model to predict prognosis in patients with gastric cancer. A total of 200 patients who underwent gastric resection...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kanda, Mitsuro, Murotani, Kenta, Tanaka, Haruyoshi, Miwa, Takashi, Umeda, Shinichi, Tanaka, Chie, Kobayashi, Daisuke, Hayashi, Masamichi, Hattori, Norifumi, Suenaga, Masaya, Yamada, Suguru, Nakayama, Goro, Fujiwara, Michitaka, Kodera, Yasuhiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922354/ https://www.ncbi.nlm.nih.gov/pubmed/29721160 http://dx.doi.org/10.18632/oncotarget.24661

Ejemplares similares

A novel dual‐marker expression panel for easy and accurate risk stratification of patients with gastric cancer
por: Kanda, Mitsuro, et al.
Publicado: (2018)

An integrated multigene expression panel to predict long-term survival after curative hepatectomy in patients with hepatocellular carcinoma
por: Kanda, Mitsuro, et al.
Publicado: (2017)

Expression of sushi domain containing two reflects the malignant potential of gastric cancer
por: Umeda, Shinichi, et al.
Publicado: (2018)

Hepatic metastasis of gastric cancer is associated with enhanced expression of ethanolamine kinase 2 via the p53–Bcl-2 intrinsic apoptosis pathway
por: Miwa, Takashi, et al.
Publicado: (2021)

Modified two‐dimensional response as surrogate marker of overall survival in patients with metastatic colorectal cancer
por: Nakayama, Goro, et al.
Publicado: (2016)

Perioperative and prognostic implication of albumin‐bilirubin‐TNM score in Child‐Pugh class A hepatocellular carcinoma
por: Sonohara, Fuminori, et al.
Publicado: (2018)

Clinical Implications of Lysyl Oxidase-Like Protein 2 Expression in Pancreatic Cancer
por: Tanaka, Nobutake, et al.
Publicado: (2018)

A prospective trial to evaluate treatment effects of a β-hydroxy-β-methylbutyrate containing nutrient for leakage at the anastomotic site after esophagectomy
por: Kanda, Mitsuro, et al.
Publicado: (2020)

Clinical Implication of Inflammation-Based Prognostic Score in Pancreatic Cancer: Glasgow Prognostic Score Is the Most Reliable Parameter
por: Yamada, Suguru, et al.
Publicado: (2016)

Identification of stromal cell-derived factor 4 as a liquid biopsy-based diagnostic marker in solid cancers
por: Shinozuka, Takahiro, et al.
Publicado: (2023)

GPR155 Serves as a Predictive Biomarker for Hematogenous Metastasis in Patients with Gastric Cancer
por: Shimizu, Dai, et al.
Publicado: (2017)

Downregulation of GPR155 as a prognostic factor after curative resection of hepatocellular carcinoma
por: Umeda, Shinichi, et al.
Publicado: (2017)

Metastatic pathway-specific transcriptome analysis identifies MFSD4 as a putative tumor suppressor and biomarker for hepatic metastasis in patients with gastric cancer
por: Kanda, Mitsuro, et al.
Publicado: (2016)

The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma—including the analysis of clinicopathological factors influencing relative dose intensity
por: Yabusaki, Norimitsu, et al.
Publicado: (2016)

Therapeutic monoclonal antibody targeting of neuronal pentraxin receptor to control metastasis in gastric cancer
por: Kanda, Mitsuro, et al.
Publicado: (2020)

Nutritional predictors for postoperative short-term and long-term outcomes of patients with gastric cancer
por: Kanda, Mitsuro, et al.
Publicado: (2016)

Albumin-Bilirubin Score Predicts Tolerability to Adjuvant S-1 Monotherapy after Curative Gastrectomy
por: Miwa, Takashi, et al.
Publicado: (2019)

The protein arginine methyltransferase 5 promotes malignant phenotype of hepatocellular carcinoma cells and is associated with adverse patient outcomes after curative hepatectomy
por: Shimizu, Dai, et al.
Publicado: (2017)

The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902)
por: Nakayama, Goro, et al.
Publicado: (2017)

Expression of cellular retinoic acid binding protein 1 predicts peritoneal recurrence of gastric cancer
por: Sakata, Kazuki, et al.
Publicado: (2022)

Phase II study of capecitabine plus oxaliplatin (CapOX) as adjuvant chemotherapy for locally advanced rectal cancer (CORONA II)
por: Hattori, Norifumi, et al.
Publicado: (2019)

Feasibility of subtotal esophagectomy with systematic lymphadenectomy in selected elderly patients with esophageal cancer; a propensity score matching analysis
por: Kanda, Mitsuro, et al.
Publicado: (2019)

A Multicenter Randomized Phase II Trial Investigating the Effect of Polyglycolic Acid Sheet on the Prevention of Pancreatic Fistula After Gastrectomy with Prophylactic Lymph Node Dissection
por: Shimizu, Dai, et al.
Publicado: (2023)

Identification of a serum-based miRNA signature for response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy
por: Niwa, Yukiko, et al.
Publicado: (2019)

Decreased expression of prenyl diphosphate synthase subunit 2 correlates with reduced survival of patients with gastric cancer
por: Kanda, Mitsuro, et al.
Publicado: (2014)

Short-term outcomes after conventional transthoracic esophagectomy
por: Niwa, Yukiko, et al.
Publicado: (2016)

Clinical utility of the platelet-lymphocyte ratio as a predictor of postoperative complications after radical gastrectomy for clinical T2-4 gastric cancer
por: Inaoka, Kenichi, et al.
Publicado: (2017)

Neoadjuvant docetaxel, oxaliplatin plus S-1 for treating clinical stage III squamous cell carcinoma of the esophagus: Study protocol of an open-label phase II trial
por: Kanda, Mitsuro, et al.
Publicado: (2021)

Prognostic significance of perioperative tumor marker levels in stage II/III gastric cancer
por: Suenaga, Yasuhito, et al.
Publicado: (2019)

Dynamin 3: a new candidate tumor suppressor gene in hepatocellular carcinoma detected by triple combination array analysis
por: Inokawa, Yoshikuni, et al.
Publicado: (2013)

A functional polymorphism in the epidermal growth factor gene predicts hepatocellular carcinoma risk in Japanese hepatitis C patients
por: Suenaga, Masaya, et al.
Publicado: (2013)

Effectiveness of plasma treatment on pancreatic cancer cells
por: HATTORI, NORIFUMI, et al.
Publicado: (2015)

Identification of the collagen type 1 alpha 1 gene (COL1A1) as a candidate survival-related factor associated with hepatocellular carcinoma
por: Hayashi, Masamichi, et al.
Publicado: (2014)

Novel prognostic implications of YTH domain family 2 in resected hepatocellular carcinoma
por: Nakagawa, Nobuhiko, et al.
Publicado: (2021)

Genome-wide identification and characterization of circular RNA in resected hepatocellular carcinoma and background liver tissue
por: Sunagawa, Yuki, et al.
Publicado: (2021)

Impact of molecular surgical margin analysis on the prediction of pancreatic cancer recurrences after pancreaticoduodenectomy
por: Sunagawa, Yuki, et al.
Publicado: (2021)

Efficacy of enteral nutrients containing β-hydroxy-β-methylbutyrate, glutamine, and arginine for the patients with anastomotic leakage after gastrectomy: study protocol of a multicenter phase II clinical trial
por: Kanda, Mitsuro, et al.
Publicado: (2018)

Multi‐institutional analysis of the prognostic significance of postoperative complications after curative resection for gastric cancer
por: Kanda, Mitsuro, et al.
Publicado: (2019)

Dihydropyrimidinase-like 3 facilitates malignant behavior of gastric cancer
por: Kanda, Mitsuro, et al.
Publicado: (2014)

Pathological tumor infiltrative pattern and sites of initial recurrence in stage II/III gastric cancer: Propensity score matching analysis of a multi‐institutional dataset
por: Nakagawa, Nobuhiko, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ljm4i4n6tiile5d1323e9lg40u